Epigenomics, the Germany-based diagnostics company with its U.S. headquarters in Seattle, said today it is restructuring operations and planning to move its U.S. headquarters to the East Coast in 2012. The company said it plans to cut 39 jobs, and retain about 45 staff at the end of 2011. Epigenomics said it is making the moves as it prepares to introduce a new colorectal cancer diagnostic test.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
